Impact of Age on Efficacy and Safety of Advanced Therapies During Induction in Ulcerative Colitis: An Individual Patient Data Pooled Analysis from Randomized Controlled Trials - PubMed
5 days ago
- #Advanced Therapies
- #Ulcerative Colitis
- #Age Impact
- Study evaluates the impact of age on the efficacy and safety of advanced therapies in moderate-to-severe ulcerative colitis (UC).
- Individual patient-level data (IPD) meta-analysis of 10 RCTs involving 6192 patients, with 10.2% aged ≥60 years.
- Efficacy of advanced therapies (TNF antagonists, vedolizumab, ustekinumab, tofacitinib) was similar in older (≥60y) vs younger adults (<60y).
- No significant treatment effect modification by age for clinical remission, endoscopic improvement, or symptomatic remission.
- Older adults had a higher risk of infections with advanced therapies compared to younger adults.
- Conclusion: Older age does not modify efficacy but increases infection risk during induction with advanced therapies in UC.